The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

Researchers replaced a chemotherapy stage with blinatumomab in ALL patients. After three years, 89% were alive and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Ahead of the ...

Please provide your email address to receive an email when new articles are posted on . “We can hopefully use these new agents in frontline therapy to increase the cure rate in adult ALL, and reduce ...

Please provide your email address to receive an email when new articles are posted on . Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy ...

The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care. Children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL) ...

Pediatric patients with relapsed or refractory B acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) who were treated with blinatumomab proceeded to hematopoietic cell transplant ...

In a final 5-year follow-up analysis of a phase 3 trial, blinatumomab consolidation therapy demonstrated superior event-free survival and overall survival than conventional chemotherapy among children ...

KCCI EIGHT NEWS AT TEN. DES MOINES SECOND GRADER JUST CELEBRATED A MAJOR MILESTONE. KCCI LAURA TERRELL HAS THE STORY THAT WILL NO DOUBT BRING YOU JOY. GABE FULLER IS USED TO THIS ROUTINE. BY NOW.

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in ...

COPENHAGEN, Denmark ― Monotherapy with the novel antibody blinatumomab (Blincyto, Amgen Inc) beat standard chemotherapy, significantly improving overall survival in adult patients with ...

The evaluation committee considered evidence submitted by Amgen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...